نتایج جستجو برای: reverse transcriptase inhibitor

تعداد نتایج: 313286  

2012
Nimish Patel Christopher D Miller

Fixed-dose combination tablets have become an important therapy option for patients infected with the human immunodeficiency virus. Fixed-dose combination rilpivirine-tenofovir-emtricitabine is a recently approved therapy option that has been extensively studied within the treatment-naïve population. When compared with efavirenz-based therapy, improved tolerability with rilpivirine-based therap...

2012
Thanyawee Puthanakit Gonzague Jourdain Piyarat Suntarattiwong Kulkanya Chokephaibulkit Umaporn Siangphoe Tulathip Suwanlerk Wasana Prasitsuebsai Virat Sirisanthana Pope Kosalaraksa Witaya Petdachai Rawiwan Hansudewechakul Naris Waranawat Jintanat Ananworanich

BACKGROUND Limited data exist for the efficacy of second-line antiretroviral therapy among children in resource limited settings. We assessed the virologic response to protease inhibitor-based ART after failing first-line non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimens. METHODS A retrospective chart review was conducted at 8 Thai sites of children who switched to PI -bas...

2015
Soo-Yon Rhee Michael R. Jordan Elliot Raizes Arlene Chua Neil Parkin Rami Kantor Gert U. Van Zyl Irene Mukui Mina C. Hosseinipour Lisa M. Frenkel Nicaise Ndembi Raph L. Hamers Tobias F. Rinke de Wit Carole L. Wallis Ravindra K. Gupta Joseph Fokam Clement Zeh Jonathan M. Schapiro Sergio Carmona David Katzenstein Michele Tang Avelin F. Aghokeng Tulio De Oliveira Annemarie M. J. Wensing Joel E. Gallant Mark A. Wainberg Douglas D. Richman Joseph E. Fitzgibbon Marco Schito Silvia Bertagnolio Chunfu Yang Robert W. Shafer Paul Richard Harrigan

The increasing prevalence of acquired and transmitted HIV-1 drug resistance is an obstacle to successful antiretroviral therapy (ART) in the low- and middle-income countries (LMICs) hardest hit by the HIV-1 pandemic. Genotypic drug resistance testing could facilitate the choice of initial ART in areas with rising transmitted drug resistance (TDR) and enable care-providers to determine which ind...

2014
Miłosz Parczewski Anna Urbańska Katarzyna Maciejewska Magdalena Witak-Jȩdra Magdalena Leszczyszyn-Pynka

INTRODUCTION Rilpivirine (RPV) is a second-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) that was recently approved for the treatment of antiretroviral-naïve individuals with HIV-1 viral load of <100,000 copies/ml. As transmission of the drug resistance mutations to this NNRTI may affect treatment outcomes, the frequency of primary, RPV-associated drug resistance mutations w...

Journal: :Journal of infection in developing countries 2014
Fausta Mosha Johanna Ledwaba Faustine Ndugulile Zipora Ng'ang'a Peter Nsubuga Lynn Morris Mabula Kasubi Andrew Swai Jurgen Vercauteren Anne-Mieke Vandamme

INTRODUCTION In Tanzania, the follow-up on antiretroviral therapy (ART) response is based on clinical outcomes. We investigated virological response and ARV resistance mutations in relation to clinical response in ARV-treated patients. METHODOLOGY A cross-sectional study of a cohort of 150 patients taking first-line ART in Dar-es-Salaam was conducted. Data were collected using standardized qu...

2018
Mikal Rekdal Aravind pai Muddukrishna BS

Etravirine is a drug used alongside other medication in the treatment of HIV and is a non-nucleoside reverse transcriptase inhibitor. It is a BCS class IV drug, having low solubility and high permeability (Drugbank, https://www.drugbank.ca/drugs/DB06414) [1]. As a result, large doses of the drug are required for treatment. Two pills have to be taken twice a day, making it a "pill burden" (Intel...

2014
Arpan Acharya Salil Vaniawala Parth Shah Rabindra Nath Misra Minal Wani Pratap N. Mukhopadhyaya

Human Immunodeficiency Virus-1 (HIV-1) drug resistance genotyping assay is a part of clinical management of HIV-1 positive individuals under treatment with highly active antiretroviral therapy (HAART). Routine monitoring of drug resistance mutations in resource limited settings like India is not possible due to high cost of commercial drug resistance assays. In this study we developed an in-hou...

2012
Marc Nischang Roger Sutmuller Gustavo Gers-Huber Annette Audigé Duo Li Mary-Aude Rochat Stefan Baenziger Ursula Hofer Erika Schlaepfer Stephan Regenass Katie Amssoms Bart Stoops Anja Van Cauwenberge Daniel Boden Guenter Kraus Roberto F. Speck

BACKGROUND Humanized mice generate a lymphoid system of human origin subsequent to transplantation of human CD34+ cells and thus are highly susceptible to HIV infection. Here we examined the efficacy of antiretroviral treatment (ART) when added to food pellets, and of long-acting (LA) antiretroviral compounds, either as monotherapy or in combination. These studies shall be inspiring for establi...

2014
Trinh Duong Ali Judd Intira Jeannie Collins Katja Doerholt Hermione Lyall Caroline Foster Karina Butler Pat Tookey Delane Shingadia Esse Menson David T. Dunn Di M. Gibb

OBJECTIVE To assess factors at the start of antiretroviral therapy (ART) associated with long-term virological response in children. DESIGN Multicentre national cohort. METHODS Factors associated with viral load below 400 copies/ml by 12 months and virologic failure among children starting 3/4-drug ART in the UK/Irish Collaborative HIV Paediatric Study were assessed using Poisson models. ...

2016
L. Marije Hofstra Nicolas Sauvageot Jan Albert Ivailo Alexiev Federico Garcia Daniel Struck David A. M. C. Van de Vijver Birgitta Åsjö Danail Beshkov Suzie Coughlan Diane Descamps Algirdas Griskevicius Osamah Hamouda Andrzej Horban Marjo Van Kasteren Tatjana Kolupajeva Leondios G. Kostrikis Kirsi Liitsola Marek Linka Orna Mor Claus Nielsen Dan Otelea Dimitrios Paraskevis Roger Paredes Mario Poljak Elisabeth Puchhammer-Stöckl Anders Sönnerborg Danica Staneková Maja Stanojevic Kristel Van Laethem Maurizio Zazzi Snjezana Zidovec Lepej Charles A. B. Boucher Jean-Claude Schmit Annemarie M. J. Wensing E. Puchhammer-Stockl M. Sarcletti B. Schmied M. Geit G. Balluch A.-M. Vandamme J. Vercauteren I. Derdelinckx A. Sasse M. Bogaert H. Ceunen A. De Roo S. De Wit F. Echahidi K. Fransen J.-C. Goffard P. Goubau E. Goudeseune J.-C. Yombi P. Lacor C. Liesnard M. Moutschen D. Pierard R. Rens Y. Schrooten D. Vaira L. P. R. Vandekerckhove A. Van den Heuvel B. Van Der Gucht M. Van Ranst E. Van Wijngaerden B. Vandercam M. Vekemans C. Verhofstede N. Clumeck K. Van Laethem D. Beshkov I. Alexiev S. Zidovec Lepej J. Begovac L. Kostrikis I. Demetriades I. Kousiappa V. Demetriou J. Hezka M. Linka M. Maly L. Machala C. Nielsen L. B. Jørgensen J. Gerstoft L. Mathiesen C. Pedersen H. Nielsen A. Laursen B. Kvinesdal K. Liitsola M. Ristola J. Suni J. Sutinen D. Descamps L. Assoumou G. Castor M. Grude P. Flandre A. Storto O. Hamouda C. Kücherer T. Berg P. Braun G. Poggensee M. Däumer J. Eberle H. Heiken R. Kaiser H. Knechten K. Korn H. Müller S. Neifer B. Schmidt H. Walter B. Gunsenheimer-Bartmeyer T. Harrer D. Paraskevis A. Hatzakis A. Zavitsanou A. Vassilakis M. Lazanas M. Chini A. Lioni V. Sakka S. Kourkounti V. Paparizos A. Antoniadou A. Papadopoulos G. Poulakou I. Katsarolis K. Protopapas G. Chryssos S. Drimis P. Gargalianos G. Xylomenos G. Lourida M. Psichogiou G. L. Daikos N. V. Sipsas A. Kontos M. N. Gamaletsou G. Koratzanis H. Sambatakou H. Mariolis A. Skoutelis V. Papastamopoulos O. Georgiou P. Panagopoulos E. Maltezos S. Coughlan C. De Gascun C. Byrne M. Duffy C. Bergin D. Reidy G. Farrell J. Lambert E. O'Connor A. Rochford J. Low P. Coakely S. O'Dea W. Hall O. Mor I. Levi D. Chemtob Z. Grossman M. Zazzi A. de Luca C. Balotta C. Riva C. Mussini I. Caramma A. Capetti M. C. Colombo C. Rossi F. Prati F. Tramuto F. Vitale M. Ciccozzi G. Angarano G. Rezza T. Kolupajeva O. Vasins A. Griskevicius V. Lipnickiene J. C. Schmit D. Struck N. Sauvageot R. Hemmer V. Arendt C. Michaux T. Staub C. Sequin-Devaux A. M. J. Wensing C. A. B. Boucher D. A. M. C. van de Vijver A. van Kessel P. H. M. van Bentum K. Brinkman B. J. Connell M. E. van der Ende I. M. Hoepelman M. van Kasteren M. Kuipers N. Langebeek C. Richter R. M. W. J. Santegoets L. Schrijnders-Gudde R. Schuurman B. J. M. van de Ven B. Åsjö A.-M. Bakken Kran V. Ormaasen P. Aavitsland A. Horban J. J. Stanczak G. P. Stanczak E. Firlag-Burkacka A. Wiercinska-Drapalo E. Jablonowska E. Maolepsza M. Leszczyszyn-Pynka W. Szata R. Camacho C. Palma F. Borges T. Paixão V. Duque F. Araújo D. Otelea S. Paraschiv A.M. Tudor R. Cernat C. Chiriac F. Dumitrescu L. J. Prisecariu M. Stanojevic Dj. Jevtovic D. Salemovic D. Stanekova M. Habekova Z. Chabadová T. Drobkova P. Bukovinova A. Shunnar P. Truska M. Poljak M. Lunar D. Babic J. Tomazic L. Vidmar T. Vovko P. Karner F. Garcia R. Paredes S. Monge S. Moreno J. del Amo V. Asensi J. L. Sirvent C. de Mendoza R. Delgado F. Gutiérrez J. Berenguer S. Garcia-Bujalance N. Stella I. de los Santos J. R. Blanco D. Dalmau M. Rivero F. Segura M. J. Pérez Elías M. Alvarez N. Chueca C. Rodríguez-Martín C. Vidal J. C. Palomares I. Viciana P. Viciana J. Cordoba A. Aguilera P. Domingo M.J. Galindo C. Miralles M. A. del Pozo E. Ribera J. A. Iribarren L. Ruiz J. de la Torre F. Vidal B. Clotet J. Albert A. Heidarian K. Aperia-Peipke M. Axelsson M. Mild A. Karlsson A. Sönnerborg A. Thalme L. Navér G. Bratt A. Blaxhult M. Gisslén B. Svennerholm I. Bergbrant P. Björkman C. Säll Å. Mellgren A. Lindholm N. Kuylenstierna R. Montelius F. Azimi B. Johansson M. Carlsson E. Johansson B. Ljungberg H. Ekvall A. Strand S. Mäkitalo S. Öberg P. Holmblad M. Höfer H. Holmberg P. Josefson U. Ryding

BACKGROUND Numerous studies have shown that baseline drug resistance patterns may influence the outcome of antiretroviral therapy. Therefore, guidelines recommend drug resistance testing to guide the choice of initial regimen. In addition to optimizing individual patient management, these baseline resistance data enable transmitted drug resistance (TDR) to be surveyed for public health purposes...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید